Rezivertinib, CAS 1835667-12-3

Product Description: Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity[1][2].

Applications: Cancer-Kinase/protease

Formula: C27H30N6O3

References: [1]Misako Nagasaka, et al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16(5):740-763./[2]Victoria L. Wilde, et al. Preclinical evidence of BPL-7711 activity in Egfr-mutant non-smallcell lung cancer ( NSCLC ) in orthotopically implanted human tumorxenografts in the lung and brain.

CAS Number: 1835667-12-3

Molecular Weight: 486.57

Compound Purity: 99.62

Research Area: Cancer

Solubility: DMSO : 125 mg/mL (ultrasonic)

Target: EGFR

• Artikelnummer: MEXHY-109189-1G
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-109189-1G
• Verpackungseinheit: 1 g
• Mengeneinheit: STK